What is the normal endometrial stripe thickness in pre‑menopausal and post‑menopausal women and how should an abnormal thickness be evaluated?

Normal Endometrial Stripe Thickness

Postmenopausal Women

In postmenopausal women, the endometrial stripe should measure ≤4 mm to be considered normal, with this threshold providing a nearly 100% negative predictive value for endometrial cancer. 1, 2

Key Thresholds and Actions:

• ≤4 mm: Normal; no further evaluation needed if asymptomatic 1, 2
• ≥5 mm: Abnormal; endometrial tissue sampling is mandatory 1, 2
• Note: The European Society for Medical Oncology uses a more conservative cutoff of ≤3 mm 1

Evaluation Algorithm for Abnormal Thickness:

• Initial imaging: Transvaginal ultrasound (TVUS) combined with transabdominal ultrasound and color Doppler to assess vascularity 1, 3
• For thickness ≥5 mm: Proceed directly to endometrial sampling using Pipelle or similar device (sensitivity 99.6% for carcinoma) 1
• If focal abnormality suspected: Perform sonohysterography (sensitivity 96-100%) to distinguish focal lesions from diffuse thickening 1
• For focal lesions: Hysteroscopy with directed biopsy is superior to blind sampling 1

Risk Stratification by Thickness:

• Asymptomatic women with thickness ≥10 mm: 16.3% malignancy risk 1
• Overall asymptomatic women with any thickening: 3.7% malignancy risk 1
• Asymptomatic women without bleeding and thickness >11 mm: 6.7% cancer risk, warranting biopsy 4

Critical Pitfalls:

• Do not rely solely on thickness measurement—abnormal echogenicity and texture correlate with pathology even when thickness appears normal 1, 2
• TVUS cannot determine etiology of thickening; tissue diagnosis is essential 1, 2
• Never proceed with ablation, embolization, or hysterectomy without first obtaining tissue diagnosis to exclude malignancy 1

---

Premenopausal Women

In premenopausal women, endometrial thickness varies physiologically throughout the menstrual cycle, and there is no validated absolute upper limit cutoff—thickness measurement alone is NOT a reliable indicator of pathology. 2

Why Thickness Doesn't Work in Premenopausal Women:

• Cyclical variation: Thickness changes with hormonal fluctuations, making any single measurement unreliable 2
• Even thickness <5 mm can miss pathology: Studies show endometrial polyps and submucosal fibroids are present in 20% of premenopausal women with endometrial stripe <5 mm 5
• Poor diagnostic accuracy: At <5 mm cutoff, sensitivity is only 74% and specificity 46% for detecting intracavitary lesions 5

What to Focus On Instead:

• Abnormal echogenicity and texture rather than absolute thickness 2
• Clinical symptoms (abnormal uterine bleeding) should drive evaluation, not thickness alone 2
• Structural abnormalities on TVUS: polyps, adenomyosis, leiomyomas 2
• Endometrial stripe abnormality (irregular appearance) is significantly associated with hyperplasia/cancer, whereas simple thickness measurement is not 6

Evaluation Algorithm for Symptomatic Premenopausal Women:

• First-line: TVUS with color/power Doppler to assess for structural causes (polyps, adenomyosis, fibroids) 2
• If ultrasound inadequate: Consider MRI with diffusion-weighted imaging for superior tissue characterization 2
• Endometrial sampling indicated based on risk factors, not thickness:
  • Age >45 years 2
  • Obesity 2
  • Unopposed estrogen exposure 2
• If focal lesion suspected: Sonohysterography (sensitivity 96-100%) or hysteroscopy for direct visualization 1, 5

Special Populations:

• Women on selective progesterone receptor modulators (e.g., ulipristal acetate): Thickness may increase to >16 mm without pathological significance; measurement is not clinically indicated during treatment 2
• Lynch syndrome patients: Do not use TVUS for screening; instead, educate on prompt reporting of abnormal bleeding to trigger endometrial biopsy regardless of ultrasound findings 2

Critical Pitfalls:

• Do not apply postmenopausal thresholds (4-5 mm) to premenopausal women—the physiology is fundamentally different 2
• Do not skip sonohysterography or hysteroscopy in symptomatic women just because thickness appears normal 5
• Absence of vascularity on Doppler does not exclude pathology—avascular polyps and retained products can occur 2

---

Special Consideration: Hormone Replacement Therapy

Postmenopausal Women on HRT:

• Combined estrogen-progestogen therapy: Does not increase endometrial cancer risk (relative hazard 0.83) 2
• Unopposed estrogen: Substantially increases risk (RR 2.3 overall, rising to RR 9.5 after 10 years) 2
• Women on HRT with thickened endometrium: 43% have hyperplasia versus 8% in non-HRT users, making biopsy essential 7